Lee Chih-Hao, Chawla Ajay, Urbiztondo Ned, Liao Debbie, Boisvert William A, Evans Ronald M, Curtiss Linda K
Howard Hughes Medical Institute, Gene Expression Laboratory, Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.
Science. 2003 Oct 17;302(5644):453-7. doi: 10.1126/science.1087344. Epub 2003 Sep 11.
The formation of an atherosclerotic lesion is mediated by lipid-laden macrophages (foam cells), which also establish chronic inflammation associated with lesion progression. The peroxisome proliferator-activated receptor (PPAR) gamma promotes lipid uptake and efflux in these atherogenic cells. In contrast, we found that the closely related receptor PPARdelta controls the inflammatory status of the macrophage. Deletion of PPARdelta from foam cells increased the availability of inflammatory suppressors, which in turn reduced atherosclerotic lesion area by more than 50%. We propose an unconventional ligand-dependent transcriptional pathway in which PPARdelta controls an inflammatory switch through its association and disassociation with transcriptional repressors. PPARdelta and its ligands may thus serve as therapeutic targets to attenuate inflammation and slow the progression of atherosclerosis.
动脉粥样硬化病变的形成由富含脂质的巨噬细胞(泡沫细胞)介导,这些细胞还会引发与病变进展相关的慢性炎症。过氧化物酶体增殖物激活受体(PPAR)γ促进这些致动脉粥样硬化细胞中的脂质摄取和流出。相比之下,我们发现密切相关的受体PPARδ控制着巨噬细胞的炎症状态。从泡沫细胞中删除PPARδ会增加炎症抑制因子的可用性,进而使动脉粥样硬化病变面积减少超过50%。我们提出了一种非常规的配体依赖性转录途径,其中PPARδ通过与转录抑制因子的结合和解离来控制炎症开关。因此,PPARδ及其配体可能作为治疗靶点,以减轻炎症并减缓动脉粥样硬化的进展。